Member Info for Heimdal

https://www1.hkexnews.hk/listedco/listconews/sehk/2021/0615/2021061500721.pdf

The Grantee is a consultant (the “Consultant”), namely Leverage IQ Iberica SL, of which
Mr. Lars Gehrmann is a director as well as the only and ultimate shareholder, providing
consultancy services to Deep Longevity, Inc (“DLI”), a wholly-owned subsidiary of the Group.
The grant of Option was due to services rendered pursuant to the terms of the consulting
agreement. The Consultant was engaged primarily to adapt the Group’s Young.AI App to
become an engaging tool that converts users to fee paying customers; and thereby enable
Young.AI to reach maximal exposure, by identifying potential improvements based on target
customers, conducting competitor research and providing written suggestions as to how best
to market the Young.AI App within the App itself, the App landing page and also in the App
Store. In addition, the Consultant was engaged to assess and evaluate how the Group’s aging
clocks could be partnered with insurance companies and define a roadmap and identify which
insurance companies should be approached, among other services. As disclosed in the Company’s announcement dated 2 September 2020 and circular dated 18 November 2020, upon acquiring DLI on 14 December 2020,
the Group acquired its developing explainable and user-friendly AI systems to track the rate of aging at
the molecular, cellular, tissue, organ, system, physiological and psychological levels. It is also developing
systems for the emerging field of longevity medicine enabling physicians to make better
decisions on the interventions that may slow down or reverse the aging processes. As
disclosed, DLI has developed Young.AI, a system for tracking predicted age at multiple levels
over time, with the first version of the Young.AI website and its Young.AI mobile App, an
application for App Store by Apple Inc., being launched on 29 September 2020. As further
disclosed in the aforesaid circular, like any other App providers, DLI planned to roll out future
versions as it improves its products. The Consultant was engaged as part of seeking to improve
the performance of Young.AI and such services were in line with past disclosures made and
the Group’s business scope.
The Board is pleased to announce that the Offer in respect of the Option to subscribe for
2,500,000 Shares has been duly accepted by the Grantee and that the Option should, following
the acceptance, be deemed to have been granted and to have taken effect on the Offer Date
(being 7 June 2021)."

Indeed, very frustrating Dougie. Largish seller not showing his hand in the Sell queue,
just dump 1m shares or so at the time into the Buy queue (ie. no limit sell orders). Heimdal

Extremely disappointing to see RPG trading at these low levels given the stellar performance of VXR and the imminent submission of Phase II in the US. The lack of cash flow from DLI and no clear business plan have been very disappointing, however, the DLI shares will still be in escrow for another four days. Not sure who the ?large off screen seller is, offloading a few million shares for the last few days. Hopefully we will bounce back and hold the 18c line tomorrow. MCap only 38m pounds / US$53m now! Heimdal

DLI in the news again:

https://geneticliteracyproject.org/2021/06/08/live-to-150-thats-what-some-ai-algorithms-say-is-possible-what-does-the-science-say/

Heimdal

Amazing to see RPG trading at sub 18c considering our VXR holding is now worth HK$ 125,553,789
eq to 29.2% of our MCap. Ohh well, sooner or later we will see a reevaluation. The VXR record date
for one-for-seven 8c shares is June 16 so I expect the VXR sp to climb further in the short term.
Maybe no market reaction before we exit our VXR position (later this year)?
Some big off screen sells the last few days, wonder if the DLI shares are out of escrow already
or maybe just Charlie finally closing his 8.6m position? Heimdal

Agree, the fair value seems to be is in a state of flux and under permanent review. On August 30 2016 RPG noted a "bargain purchase on the acquisition of Plethora Solutions Holdings of US$31.69 million" and as such we recorded a profit for the six months ended June 30, 2016. For 2017-18-19 we depreciated Fortacin with US$14m each year as Bignose noted, but this was changed in 2020 to US$ 25m after a new independent review, and then reduced to 19.41m on March 30, 2021.
Interim results for the six months ended 30 June 2021 will be interesting given recent developments.
Will also be interesting to follow the share price movements as we move ever closer to FDA Phase II submission in June, a major milestone! Would be good to break out of the very narrow trading range and continue the uptrend. Heimdal

No worries Dougie. Amortization is an accounting technique used to periodically lower the book value of an intangible asset, similar to depreciation. My question is how much RPG can depreciate Fortacin given recent FDA, EU and China developments. Maybe we have reached the end of the road and we will shortly see a positive profit alert? A bit more uplifting than the relentless profit warnings.. lol

Plethora Solutions was purchased for US$145m back in 2015, since then we have seen a combined amortization of US$86.4m over a 5 year period:

2017: US$ 14m
2018: US$ 14m
2019: US$ 14m
2020: US$ 25m (after a new independent review)
2021: US$ 19.41m

Current value of Fortacin is thus only US$ 58.6m and I wonder if there will be any more write downs on our main asset?

Will we see yet another profit warning in July or is the write off now completed given the Rx - OTC change in the EU, significant FDA developments, China progress etc?

Could we possibly see a positive profit alert issued in July primarily based on our VXR holding which is now valued at HK$120,000,000 or c. 28% of RPG's MCap?

A positive profit alert could be issued as early as June (example June 11, 2012) but more likely to be July.

The RPG share price is somewhat tracking the Hang Seng Index, we had a high of 31,183 on Feb 18 and now trading sideways. Other shares like Mountain Valley also peaked at that time @ C$2.19 and is now retraced back to just C$ 0.47,
I hope Charlie dingwall is doing OK after his 575 sell off on March 22 when Mountain Valley were trading at C$ 1.32.. Cathie Wood's ARK, the darling of the market last year is down 37% this year.. Not always easy to navigate in this market! I think RPG is holding up well and I am still very hopeful the sp will move north this year generated by our growing VXR holding, FDA, China and EU progress combined with potential positive DLI / further longevity developments under the new reinvigorated Endurance banner.

Heimdal.

Heimdal

HOME entry page much improved and looks very sharp indeed. However, the DLI website still need an ABOUT page with Vision, Leadership, Video Presentation etc similar to RPG. They also need to update the CAREERS page which is well outdated. INVESTOR RELATIONS is also old hat so still a bit of tidying up to do.

575 still trading sideways but BUY side building, with c. 3m unfilled buy orders at =/+18c just before close. Prudential Sec noted.

Let's see what next week will bring with name change and all, hopefully a new beginning and a brighter future for all holders. No need to change company name if it is not coupled with a new vision, new energy and dynamics.

A fair bit of news to look forward to (not least FDA Phase II submission next month - a major milestone!).

Heimdal

VXR looking very bullish and our holding is now valued at HK$120,000,000 / >27% of RPG's MCap.
When will we see a market reaction? Heimdal

Amendment: largest jump in recent times was of course on the Rx - OTC switch on SEPT 4 with 572m shares traded and an intraday jump from 9.6c to 24c.. still, we can get big jumps here in HK on no news.

High volume going through fellas. If you look back on the chart you will see the two largest recent jumps in the sp
were not associated with any announcements: on JAN 31 2020 98m shares traded and the sp jumped from
10c -> 19.1c (intraday) and again on FEB 16 2021 with 62m and a jump from 21c -> 26.5c a week after Market Update.
I think we are overdue for a lift given: 1) significant increase in VXR holding which now underpin the sp and 2) we are moving very close to submitting completed Phase II data to FDA (major milestone!). Heimdal

Given the last Market Update I expect the following news flow for the rest of 2021:

Name change (May 28)
Confirm subscription of 3,407,063 new VXR shares @ 8c / each (June)
Confirm Phase II submission to FDA (end of June)
Potential positive result from ongoing license discussions in USA (June - ?)
Taiwan launch (June - July)
Potential positive profit warning (Aug)
Confirm China clinical trial (Oct)
Update on OTC progress in the EU (June - ?)
Potential VXR block trade (> June)
Confirm FDA Phase III start (Q4)
DLI cash flow update (?)
Japan / ROW progress (?)
Potential new ventures (?)

What would move the sp? VXR block trade exit @ + HK$100m, FDA Phase II/III progress, China CT start, positive EU news, new ventures and securing a deal in the USA (the big one which could come out of the blue any day).

Markets are choppy at the moment but RPG should hold up well given the low Market Cap, our VXR holding
and expected news flow.

Heimdal

Cheer up Bignose this a long term hold which will eventually come good. With the vital US commercialization moving ever closer this could take off any day. For now we have support around the 18-19c level and resistance around 20c which will be broken sooner or later. WRT our VXR holding, this is a good story, and it is clearly in all holders interest that the BoD take up our full entitlement of 3,407,063 new shares @ 8c each with 1,703,531 free attached options for a mere US$212,744 which is just 6.6% of the US$3.2m received recently from Wanbang. Heimdal

Agree, a very positive, well crafted and comprehensive Market Update Dougie. Unfortunate delay wrt China and roll out Taiwan but on track and positive news on USA. Also good comprehensive update on DLI. The HK market is soft, drifting 11% lower since the FEB 17 high. VXR looking solid at 71c up 2% today. Will be interesting to see how long we will hold. Maybe there will be a stronger market reaction if we offload at + HK$100,000,000. RPG will bounce in due course as the significant rise in VXR is not factored in to the sp - reflecting a very low Market Cap. A 5 star bargain! Heimdal

https://www.marketwatch.com/story/mining-stocks-climb-in-london-as-copper-surges-to-all-time-highs-11620398933

Upward and onward!

Heimdal

The May Market Update is not far away and it could include the following:

Significant increase in the value of our VXR holding - (+HK$100,000,000) underpinning the RPG share price
Confirmation of Macao launch
Confirmation of Taiwan launch
Confirmation of USA Phase II study submission
Confirmation of China clinical trial start
USA marketing study update
News on OTC roll out in EU next month
Japan
DLI status

BoD might hold the Market Update back to relaunch RPG with a new name on MAY 28 and hit the market at full blast.

Happy days!

Heimdal

Agree Bignose. They have certainly changed strategy. We had frequent updates for a while, about six in two months and now hardly any news - only selected holders like The Italian getting inside information on Macao launch... Not sure why they suddenly changed news flow tactics. Sold down on very low vol. Looks like they want to keep it in a tight trading range around 19c. Heimdal

VXR bouncing back strongly today, 1 hour before close it is up 14.4% at 75.5c.
It is a good story and with few listed Cu companies on the ASX there are not many alternatives for the local punters.
With a value of HK$108,000,000 our VXR holding is equal to 23.8% of the RPG MCap (or 4.5c). Heimdal

Morning Bignose, In general I share your cautionary views on resource projects and "big wigs". However, I think Bill Beament and VXR will deliver. The timing is perfect and the project is solid. Sulphur Springs is a low CAPEX and rapid payback project (given the shallow high grade nature of the deposit). I understand c. AU$200m is required in CAPEX and the bulk (ie. AU$158m) is already sorted. Approved Term Sheet for finance already received from global commodity trader Trafigurar for AU$100m of senior debt funding : https://wcsecure.weblink.com.au/pdf/VXR/02130406.pdf . An up to AU$58m strategic funding package organized by Bill Beament was secured on FEB 24. Copper prices up again last night with analysts predicting prices up to $15,000/t a 50% increase from here.

All in all VXR might well be a game changer for Regent on the short to medium track. Exit could well be an off market block trade with a super fund or similar situation but I doubt Jamie will offload for <$1.35/share or $32.1m / HK$193m.

Heimdal